During the last session, GeneDx Holdings Corp (NASDAQ:WGS)’s traded shares were 0.71 million, with the beta value of the company hitting 1.98. At the end of the trading day, the stock’s price was $98.01, reflecting an intraday gain of 0.76% or $0.74. The 52-week high for the WGS share is $115.60, that puts it down -17.95 from that peak though still a striking 92.12% gain since the share price plummeted to a 52-week low of $7.72. The company’s market capitalization is $2.75B, and the average trade volume was 999.81K shares over the past three months.
GeneDx Holdings Corp (WGS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. WGS has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.11.
GeneDx Holdings Corp (NASDAQ:WGS) trade information
GeneDx Holdings Corp (WGS) registered a 0.76% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.76% in intraday trading to $98.01, hitting a weekly high. The stock’s 5-day price performance is -4.71%, and it has moved by 45.89% in 30 days. Based on these gigs, the overall price performance for the year is 1022.68%.
The consensus price target of analysts on Wall Street is $70, which implies a decrease of -40.01% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $70 and $70 respectively. As a result, WGS is trading at a premium of 28.58% off the target high and 28.58% off the low.
GeneDx Holdings Corp (WGS) estimates and forecasts
In the rating firms’ projections, revenue will increase 17.40% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 79.9M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 85.32M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 62.42M and 70.51M respectively. In this case, analysts expect current quarter sales to grow by 27.99% and then jump by 20.99% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 96.65%. While earnings are projected to return 248.68% in 2025, the next five years will return 119.03% per annum.
WGS Dividends
GeneDx Holdings Corp is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 2.47 million shares, is of CORVEX MANAGEMENT LP’s that is approximately 9.2937% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $64.66 million.
Also, the Mutual Funds coming in first place with the largest holdings of GeneDx Holdings Corp (WGS) shares are Alger Small Cap Focus Fund and Vanguard Total Stock Market Index Fund . Data provided on Oct 31, 2024 indicates that Alger Small Cap Focus Fund owns about 461.76 shares. This amounts to just over 1.65 percent of the company’s overall shares, with a $45.26 million market value. The same data shows that the other fund manager holds slightly less at 410.78, or about 1.46% of the stock, which is worth about $40.26 million.
